Reagents and instruments for immunology, cell biology and molecular biology.
 
> Enoxaparin [679809-58-6]

Enoxaparin [679809-58-6]

Print Print
Please log in

Cat# HY-109509-50mg

Size : 50mg

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.

For research use only. We do not sell to patients.

Enoxaparin Chemical Structure

Enoxaparin Chemical Structure

CAS No. : 679809-58-6

This product is a controlled substance and not for sale in your territory.

Based on 1 publication(s) in Google Scholar

Description

Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19[1][2][3].

In Vitro

Enoxaparin (0-70 μg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Enoxaparin Related Antibodies

Cell Viability Assay[1]

Cell Line: HEK293T TMPRSS2 cells, hAEc
Concentration: 0, 8.8, 35, 70 µg/mL
Incubation Time: 90 min
Result: Significantly inhibited TMPRSS2 activity at the 90 min incubation period at 35 and 70 µg/mL, enhanced AAT inhibition of TMPRSS2 activity, and augmented AAT inhibition of HCoV-229E infection of hAEc.
In Vivo

Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male Wistar rats (350-450 g, TBI-treated)[2]
Dosage: 0 mg/kg, 1 mg/kg
Administration: SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.
Result: Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.
Clinical Trial
CAS No.

679809-58-6
Appearance

Solid

Color

White to off-white

SMILES

[Enoxaparin]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL

*"≥" means soluble, but saturation unknown.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

SDS (251 KB)

COA (243 KB)

Handling Instructions (2659 KB)
References

  • [1]. Bai X, et al. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 Mar 25;12(1):5207.  [Content Brief]

    [2]. Župan Ž, et al. Effects of enoxaparin in the rat hippocampus following traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1846-56.  [Content Brief]

    [3]. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99.  [Content Brief]

  • [1]. Bai X, et al. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 Mar 25;12(1):5207.

    [2]. Župan Ž, et al. Effects of enoxaparin in the rat hippocampus following traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1846-56.

    [3]. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Enoxaparin Related Classifications

  • Metabolic Enzyme/Protease Anti-infection
  • Factor Xa Thrombin SARS-CoV
Help & FAQs

Keywords:

Enoxaparin679809-58-6PK 10169PK10169PK-10169Factor XaThrombinSARS-CoVFxaSARS coronavirusLiver fibrosisThioacetamidecoronavirusinfectionCOVID-19traumatic brain injuryneuroprotectiveInflammationblood clotsacute coronary syndromesInhibitorinhibitorinhibit